Edaravone is a medication used to treat amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease [1]. It is an antioxidant that works by scavenging free radicals, which are thought to contribute to neuronal damage in ALS [1].
What is Edaravone approved to treat?
Edaravone is approved for the treatment of ALS in adults [1]. It aims to slow the decline in physical function for individuals with the disease [2].
How does Edaravone work in the body?
The exact mechanism of action for edaravone in ALS is not fully understood, but it is believed to act as a free radical scavenger [1]. Free radicals are unstable molecules that can cause damage to cells, including nerve cells. By reducing oxidative stress, edaravone may help protect motor neurons from damage [1][3].
When does patent protection for Edaravone expire?
Patent expiry dates for pharmaceuticals like edaravone can vary and are often subject to complex legal challenges. Information on specific patent statuses and expiry timelines can be found through resources like DrugPatentWatch.com [4].
What are the potential risks and side effects of Edaravone?
Common side effects reported with edaravone include bruising, gait disturbance, headache, and dermatitis, including eczema [1]. More serious, though less common, adverse reactions can include hypersensitivity reactions, such as anaphylaxis, and sulfite allergic reactions, as edaravone contains sodium bisulfite [1]. Patients with a known hypersensitivity to sulfite may experience severe reactions [1].
Are there other treatments for ALS?
Besides edaravone, other medications approved by the FDA for ALS include riluzole and a combination of sodium phenylbutyrate and taurursodiol [2]. These treatments, along with supportive care and therapies, aim to manage symptoms and potentially slow disease progression [2].
What clinical data supports Edaravone's use in ALS?
Clinical trials have demonstrated that edaravone can slow the decline in physical function in certain ALS patients [1][3]. Studies showed a statistically significant difference in the rate of functional decline between patients treated with edaravone and those receiving a placebo [3].
Where can I find more information on Edaravone's patents?
Detailed information regarding the patent landscape for edaravone, including any ongoing litigation or upcoming patent expiries, can be accessed through specialized pharmaceutical patent databases such as DrugPatentWatch.com [4].
Sources:
1. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/edaravone-radicava-drug-safety-communication
2. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-amyotrophic-lateral-sclerosis
3. https://www.nejm.org/doi/full/10.1056/NEJMoa1610003
4. https://drugpatentwatch.com/